Koyfin Home > Directory > Health Care > Aimmune Therap > EBITDA / Interest Expenses

Aimmune Therap EBITDA / Interest Expenses Chart (AIMT)

Aimmune Therap annual/quarterly EBITDA / Interest Expenses from 2018 to 2020. EBITDA / Interest is the interest coverage ratio and measures the ability of a company to service its debt.
  • Aimmune Therap EBITDA / Interest Expenses for the quarter ending June 06, 2020 was $-20m a -145.04% increase of 29m year over year
  • Aimmune Therap EBITDA / Interest Expenses for the last 12 months ending June 06, 2020 was $-34m a -157.26% increase of 54m year over year
  • Aimmune Therap Annual EBITDA / Interest Expenses for 2019 was $-49m a -3,743.02% increase of 1,842m from 2018
  • Aimmune Therap Annual EBITDA / Interest Expenses for 2018 was $-1,892m a 38.64% decrease of -731m from 2017
  • Aimmune Therap Annual EBITDA / Interest Expenses for 2017 was $-1,161m a 95.50% decrease of -1,108m from 2016
Other Ratios Metrics:
  • Aimmune Therap Total Debt / Capital for the quarter ending December 12, 2017 was $0m
  • Aimmune Therap Other Liabilities for the quarter ending December 12, 2018 was $3m a 9.82% increase of 0m year over year
  • Aimmune Therap Total Debt / Equity for the quarter ending December 12, 2017 was $0m
View Chart On Koyfin

Quarterly AIMT EBITDA / Interest Expenses Data

06/2020$-20m
03/2020$-37m
12/2019$-13m
06/2019$-48m
03/2019$-47m
12/2018$-513m

Annual AIMT EBITDA / Interest Expenses Data

2019$-49m
2018$-1,892m
2017$-1,161m
2013$-52m